Effect of low-dose calcium supplements on bone loss in perimenopausal and postmenopausal Asian women: A randomized controlled trial

• Published in: Journal of bone and mineral research 2012-11, Vol.27 (11), p.2264-2270
• Main Authors: Nakamura, Kazutoshi, Saito, Toshiko, Kobayashi, Ryosaku, Oshiki, Rieko, Kitamura, Kaori, Oyama, Mari, Narisawa, Sachiko, Nashimoto, Mitsue, Takahashi, Shunsuke, Takachi, Ribeka
• Format: Article
• Language: English
• Subjects: Age; Aged; Asian Continental Ancestry Group; Biological and medical sciences; Biomarkers - blood; BONE DENSITY; Bone Density - drug effects; Bone loss; Bone mineral density; Bone Resorption - blood; Bone Resorption - drug therapy; Bone Resorption - physiopathology; CALCIUM; Calcium - blood; Calcium carbonate; Calcium, Dietary - administration & dosage; Calcium, Dietary - pharmacology; Calcium, Dietary - therapeutic use; Cardiovascular diseases; Dietary Supplements; Dose-Response Relationship, Drug; Female; Femur; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Humans; Intention to Treat Analysis; Middle Aged; Older people; OSTEOPOROSIS; Perimenopause - blood; Perimenopause - drug effects; Placebos; Post-menopause; POSTMENOPAUSE; Postmenopause - blood; Postmenopause - drug effects; RANDOMIZED CONTROLLED TRIAL; Skeleton and joints; Spine (lumbar); Statistical analysis; Supplementation; Treatment Outcome; Vertebrates: osteoarticular system, musculoskeletal system
• ISSN: 0884-0431; 1523-4681
• DOI: 10.1002/jbmr.1676

Current standard‐dose calcium supplements (eg, 1000 mg/d) may increase the risk for cardiovascular events. Effectiveness of lower‐dose supplements in preventing bone loss should thus be considered. This study aimed to assess whether calcium supplements of 500 or 250 mg/d effectively prevent bone loss in perimenopausal and postmenopausal Japanese women. We recruited 450 Japanese women between 50 and 75 years of age. They were randomly assigned to receive 500 mg of calcium (as calcium carbonate), 250 mg of calcium, or placebo daily. Medical examinations conducted three times over a 2‐year follow‐up period assessed bone mineral density (BMD) of the lumbar spine and femoral neck. One‐factor repeated measures ANOVA was used for statistical tests. Subgroup analyses were also conducted. Average total daily calcium intake at baseline for the 418 subjects who underwent follow‐up examinations was 493 mg/d. Intention‐to‐treat analysis showed less dramatic decreases in spinal BMD for the 500‐mg/d calcium supplement group compared to the placebo group (1.2% difference over 2 years, p = 0.027). Per‐protocol analysis (≥80% compliance) revealed that spinal BMD for the 500‐mg/d and 250‐mg/d calcium supplement groups decreased less than the placebo group (1.6%, p = 0.010 and 1.0%, p = 0.078, respectively), and that femoral neck BMD for the 500‐mg/d calcium supplement group decreased less relative to the placebo group (1.0%, p = 0.077). A low‐dose calcium supplement of 500 mg/d can effectively slow lumbar spine bone loss in perimenopausal and postmenopausal women with habitually low calcium intake, but its effect on the femoral neck is less certain. Calcium supplementation dosage should thus be reassessed. (Clinical Trials Registry number: UMIN000001176). © 2012 American Society for Bone and Mineral Research.